Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Gedatolisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Celcuity Presents PIK3CA WT VIKTORIA-1 Results at 2025 SABCS
    Celcuity Presents PIK3CA WT VIKTORIA-1 Results at 2025 SABCS

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3204248/0/en/Celcuity-Presents-Updated-Results-from-the-PIK3CA-Wild-Type-Cohort-of-the-Phase-3-VIKTORIA-1-Trial-at-the-2025-San-Antonio-Breast-Cancer-Symposium.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Celcuity to Present Updated VIKTORIA-1 Data at SABCS 2025
    Celcuity to Present Updated VIKTORIA-1 Data at SABCS 2025

    26 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/26/3195381/0/en/Celcuity-to-Present-Updated-Data-from-the-PIK3CA-Wild-Type-Cohort-of-the-Phase-3-VIKTORIA-1-Trial-at-the-2025-San-Antonio-Breast-Cancer-Symposium.html

    GLOBENEWSWIRE
    26 Nov 2025
    Share Share
    Celcuity Submits NDA for Gedatolisib in HR+/HER2- Breast Cancer
    Celcuity Submits NDA for Gedatolisib in HR+/HER2- Breast Cancer

    17 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/17/3189580/0/en/Celcuity-Announces-Completion-of-Submission-of-Its-New-Drug-Application-to-the-U-S-FDA-for-Gedatolisib-in-HR-HER2-PIK3CA-Wild-Type-Advanced-Breast-Cancer.html

    GLOBENEWSWIRE
    17 Nov 2025
    Share Share
    Celcuity Reports Q3 2025 Financial Results & Corporate Update
    Celcuity Reports Q3 2025 Financial Results & Corporate Update

    12 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/12/3186736/0/en/Celcuity-Inc-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    12 Nov 2025
    Share Share
    Celcuity Updates PIK3CA Mutated Cohort In VIKTORIA-1 Trial
    Celcuity Updates PIK3CA Mutated Cohort In VIKTORIA-1 Trial

    18 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/18/3168948/0/en/Celcuity-Provides-Update-on-Status-of-the-PIK3CA-Mutated-Cohort-of-Phase-3-VIKTORIA-1-Trial-and-Releases-Additional-Data-Analysis-From-Phase-1b-Clinical-Trial.html

    GLOBENEWSWIRE
    18 Oct 2025
    Share Share
    Celcuity Updates Phase 1 Data On Gedatolisib Plus Darolutamide
    Celcuity Updates Phase 1 Data On Gedatolisib Plus Darolutamide

    18 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/18/3168947/0/en/Celcuity-Presents-Updated-Data-at-the-2025-ESMO-Congress-from-Phase-1-Study-Evaluating-Gedatolisib-Plus-Darolutamide-in-Men-with-Metastatic-Castration-Resistant-Prostate-Cancer-mCR.html

    GLOBENEWSWIRE
    18 Oct 2025
    Share Share